Abiopharma

(10% Negative) INTELLIA THERAPEUTICS, INC. (NTLA) Announces Delay in attacks Trials for six-month efficacy evaluation period Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(30% Negative) BANK OF MARIN BANCORP (BMRC) Reports Q2 2026 Financial Results

(19% Negative) VERADERMICS, INC (MANE) Announces Delay in improvement Trials for non-vellus target area hair count (TAHC) of 30 Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(99% Neutral) JAGUAR HEALTH, INC. (JAGX) Files Form 8-K

(99% Neutral) ACM RESEARCH, INC. (ACMR) Reports Q2 2026 Financial Results

(35% Negative) M-TRON INDUSTRIES, INC. (MPTI) Announces Business Combination

(25% Negative) HUT 8 CORP. (HUT) Reports Q2 2026 Financial Results

(99% Neutral) HEALTH CATALYST, INC. (HCAT) Announces Business Combination

(30% Negative) SIERRA BANCORP (BSRR) Reports Q2 2026 Financial Results

(30% Negative) NORWOOD FINANCIAL CORP (NWFL) Reports Q2 2026 Financial Results